Consensus Mesoblast Limited

Equities

MSB

AU000000MSB8

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 05:10:16 13/02/2026 GMT			5-day change	1st Jan Change
2.380 ^AUD	-2.86%		+6.73%	-12.50%

02-13	Mesoblast Leads Global Regenerative Therapy Expansion
02-12	Mesoblast Limited Provides Data Presented at the February 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy and the Center for Blood and Marrow Transplant Research in Salt Lake City, Utah	CI

Evolution of the Average Target: Mesoblast Limited

Evolution of the Target Price: Mesoblast Limited

Changes in Analyst Recommendations: Mesoblast Limited

5e9ed60c52c36.7KXw7CR0uutN2JoZTv00Uj9jHQnDVqRkw8o-Role6dg.psOynnUG26IZsNdcdq0BEwkPbWCQLt5XsYxfH-gkg6iu3YnbYUT_ngGZ-Q~13cab77dcd9e538f76de8591f7b40beb

Analysts' recommendations: Mesoblast Limited

01-14	Mesoblast Likely to Complete More Ryoncil Therapies than Expected in Fiscal 2026, Says Jefferies	MT
11-05	Mesoblast to Meet US FDA on Opioid Cessation Data for Back Pain Drug	MT
11-05	Mesoblast Says US FDA Schedules Meeting in Early December to Discuss Data from Chronic Low Back Pain Study	MT
11-05	Mesoblast to meet with FDA next month to discuss rexlemestrocel-L and opioid cessation	RE
13/10/25	Mesoblast to Complete Ryoncil Treatment in Fiscal Year 2026 on 63 Patients, Jefferies Says	MT
05/08/25	Canaccord Genuity Starts Mesoblast at Buy with AU$2.97 Price Target	MT
23/12/24	Jefferies Downgrades Mesoblast to Hold From Buy; Price Target is AU$2.30	MT
24/09/24	Maxim Upgrades Mesoblast to Buy From Hold	MT
29/08/24	Jefferies Upgrades Mesoblast to Buy From Hold; Price Target is AU$1.10	MT
31/08/23	Cantor Fitzgerald Adjusts Price Target on Mesoblast to $17 From $23, Maintains Overweight Rating	MT
07/08/23	Maxim Downgrades Mesoblast to Hold From Buy	MT
04/08/23	Piper Sandler Downgrades Mesoblast to Neutral From Overweight, Adjusts Price Target to $2 From $7	MT
04/08/23	William Blair Downgrades Mesoblast to Market Perform From Outperform	MT
04/08/23	Chardan Trims Price Target on Mesoblast to $1.50 From $2, Maintains Sell Rating	MT
30/05/23	Chardan Cuts Price Target on Mesoblast to $2 From $2.50 Reflecting Increased Share Count Dilution, Reiterates Sell Rating	MT
01/02/23	Cantor Fitzgerald Reiterates Mesoblast at Overweight With $23 Price Target	MT
06/12/22	Jefferies Downgrades Mesoblast to Hold From Buy	MT
06/09/22	Piper Sandler Starts Mesoblast at Overweight With $7 Price Target	MT
03/06/22	Chardan Lowers Mesoblast's Price Target to $2.50 From $6.50, Maintains Sell Rating	MT
31/08/21	MESOBLAST : Jefferies Downgrades Mesoblast to Hold From Buy	MT
31/08/21	MESOBLAST : Chardan Adjusts Mesoblast's Price Target to $6.50 From $7.50, Maintains Sell Rating	MT
07/04/21	MESOBLAST : Maxim Group Upgrades Mesoblast to Buy From Hold, Sets $18 Price Target	MT
19/01/21	MESOBLAST : Jefferies & Co Downgrades Mesoblast to Hold From Buy	MT
22/12/20	MESOBLAST : Maxim Downgrades Mesoblast to Hold From Buy	MT
15/12/20	MESOBLAST : RBC Capital Adjusts Mesoblast's Price Target to $11 From $12, Maintains Sector Perform-Speculative Risk Rating	MT